Dapagliflozin fares better than glipizide as add-on diabetes drug

07/21/2013 | InternalMedicineNews.com (free registration)

A Phase III study of 814 patients with type 2 diabetes indicated that 67% of those who used dapagliflozin as an add-on to metformin saw reductions in both weight and HbA1C levels at 52 weeks, compared with 21% of those who used glipizide as an add-on treatment. The findings were presented at the American Diabetes Association's 73rd Scientific Sessions.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Fremont, CA